Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: Rationale, preliminary results and perspectives

Tumori

Volumn 89, Issue 4, 2003, Pages 361-367

  Corvò, Renzo ^a   Pastrone, Ilaria ^a   Scolaro, Tindaro ^a   Marcenaro, Michela ^b   Berretta, Laura ^b   Chiara, Silvana ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ist Naz per la Ricerca sul Cancro ^*

Author keywords

Capecitabine; Chemotherapy; Radiotherapy; Rectal cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TEGAFUR; UFT;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; QUALITY OF LIFE; RADIATION DOSE; RECTUM CANCER; REVIEW; SKIN TOXICITY; THROMBOSIS; VASCULAR ACCESS;

EID: 0142041932     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900403     Document Type: Review

References (53)

1. Nelson H, Sargent DJ: Refining multimodal therapy for rectal cancer. N Engl J Med, 345: 690-692, 2001.
2. Wils J, O'Dwyer P, Labianca R: Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol, 12: 13-22, 2001.
3. Glynne-Jones R, Debus J: Improving chemoradiotherapy in rectal cancer. Oncologist 6 (suppl 4): 29-34, 2001.
4. Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP: Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long-term follow-up. Int J Radiat Oncol Biol Phys, 42: 51-57, 1998.
5. Glimelius B, Pahlman L: Perioperative radiotherapy in rectal cancer. Acta Oncol, 38: 23-32, 1999.
6. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, Van de Velde CJ: Dutch Colorectal Cancer Group: preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345: 638-646, 2001.
7. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med, 336: 980-987, 1997.
8. Lawrence TS, Tepper JE, Blackstock AW: Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol, 7: 260-266, 1997.
9. Rich TA: Irradiation plus 5-fluorouracil: cellular mechanisms of action and treatment schedules. Semin Radiat Oncol, 7: 267-273, 1997.
10. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol, 16: 301-308, 1998.
11. Galmarini CM, Mackey JR, Dumontet C: Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol, 3: 415-424, 2002.
12. Rougier P, Paillot B, LaPlanche A, Morvan F, Seitz JF, Rekacewicz C, Laplaige P, Jacob J, Grandjouan S, Tigaud JM, Fabri MC, Luboinski M, Ducreux M: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer, 33: 1789-1793, 1997.
13. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol, 15: 110-115, 1997.
14. Diasio RB: An evolving role for oral fluoropyrimidine drugs. J Clin Oncol, 20: 894-896, 2002.
15. Cunningham D, Coleman R: New options for outpatient chemotherapy - the role of oral fluoropyrimidines. Cancer Treat Rev, 27: 211-212, 2001.
16. Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA, 90: 11064-11068, 1993.
17. Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH: Phase I trials of uracil-tegafur (UFT) using 5 and 28-day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs, 7: 728-733, 1996.
18. Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA, Cantalapiedra R, Marcos P, Alvarado A, Garcia Alfonso P, Herranz R, Alvarez E: Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs tegafur. Int J Radiat Oncol Biol Phys, 51: 1264-1270, 2001.
19. Van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol, 18: 2772-2779, 2000.
20. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34: 1274-1281, 1998.
21. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol, 55: 1091-1097, 1998.
22. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol, 45: 291-297, 2000.
23. Harstrick A: Future treatment options with capecitabine. Semin Oncol, 27 (5 Suppl 10): 149-152, 2000.
24. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K: The Xeloda Colorectal Cancer Study Group: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 37: 597-604, 2001.
25. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 19: 2282-2292, 2001.
26. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res, 5: 2948-2953, 1999.
27. Collie-Duguid ES, Johnston SJ, Boyce L, Smith N, Cowieson A, Cassidy J, Murray GI, McLeod HL: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer, 94: 297-301, 2001.
28. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol, 16: 1795-1802, 1998.
29. Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF: A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys, 53: 675-679, 2002.
30. Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, Frings G: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol, 20: 3983-3991, 2002.
31. Ngan S, Zalcberg J, Kell A, Michalel M, MacKay J, Lim Joon D, McKendrick J, Martin A, Sharp K: A phase I study of capecitabine with radiotherapy for locally advanced potentially operable rectal cancer. Proc ASCO, 20: 591:149A, 2001.
32. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 54: 403-408, 2002.
33. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the MD Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys, 44: 1027-1038, 1999.
34. Chen ET, Mohiuddin M, Brodovsky H: Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys, 30: 169-175, 1994.
35. Yoon W, Choi J, Kim J, Kim T, Lim K, Hwang B, Song K, Jang J, Kim J, Kim J, Cho M: Enhanced tumoricidal effect of preoperative chemoirradiation using capecitabine for locally advanced rectal cancer. Proc ASCO, 20: 2165: 104b, 2001.
36. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 9: 1053-1071, 1998.
37. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med, 345: 144-145, 2001.
38. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol, 16: 2943-2952, 1988.
39. Van Cutsem E, Verslype C, Integration of new cytotoxic agents in the management of advanced colorectal cancer: where are we now and where do we go? Educational Book ASCO, 240-247, 2002.
40. McMullen KP, Blackstock AW: Chemoradiation with novel agents for rectal cancer. Cl Colorectal Cancer, 2: 24-30, 2002.
41. Roche Data on file - Xeloda Satellite symposium - Fourth Inter Conference Perspectives in Colorectal Cancer, Barcelona, 21 June 2002.
42. Kennedy AS, Van Echo DA, Moesinger R, Shibata D, Darwin P, Haluszka O: Phase I studies using capecitabine combined with conformal radiation therapy (RT), paclitaxel, CPT-11 and celecoxib in gastrointestinal malignancies. Proc ASCO, 21: 3021, 300B, 2002.
43. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys, 53: 664-674, 2002.
44. Scott N, Hale A, Deakin M, Hand P, Adab FA, Hall C, Williams GT, Elder JB: A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol, 24: 169-173, 1998.
45. Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC, Compton CC: Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol, 13: 1417-1424, 1995.
46. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer, 82: 560-567, 2000.
47. McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer, 79: 191-203, 1999.
48. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol, 13: 308-317, 2002.
49. Corvò R: Rectal cancer: sphincter preservation with preoperative radiation therapy and conservative surgery. Rec Prog Med, 1: 41-44, 2001.
50. Berger C, de Muret A, Garaud P, Chapet S. Bourlier P, Reynaud-Bougnoux A, Dorval E, de Calan L, Huten N, le Folch O, Calais G: Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys, 37: 619-627, 1997.
51. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, Guillemin F, Bey P: Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys, 42: 935-941, 1998.
52. Gerard JP, Chapet O, Morignat E, Romestaing P, Mornex F, Acharki A: Preoperative radiotherapy of rectal cancer. The Lyons experience, 1985-1996. Prognostic study apropos of 312 patients. Ann Chir, 53: 1003-1010, 1999.
53. Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DE, Marks G: Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys, 46: 883-888, 2000.